Serveur d'exploration sur l'Indium

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Somatostatin analogue scintigraphy in carcinoid tumours

Identifieur interne : 000239 ( Main/Exploration ); précédent : 000238; suivant : 000240

Somatostatin analogue scintigraphy in carcinoid tumours

Auteurs : RBID : ISTEX:259_1993_Article_BF00169802.pdf

English descriptors

Abstract

Scintigraphy with iodine-123 or indium-111 labelled somatostatin analogue (octreotide) was performed in 52 patients diagnosed as, suspected of, or at risk of having carcinoid tumours. In 32 of 37 (86%) patients in whom histologically proven carcinoids were still present, known tumour sites were visualized. Using 123I-coupled octreotide, 24 of 40 (60%) known extrahepatic sites were visualized, whereas all of 12 (100%) extrahepatic lesions were visualized after injection of 111In-coupled octreotide. Known liver metastases were not distinctly visualized with octreotide scintigraphy in 12 of 24 patients. In all but two of these cases, an even distribution of radioactivity in the liver was observed. This is most probably due to the fact that these liver metastases accumulated about as much radioactivity as does normal liver tissue. Previously unsuspected localizations or sites not recognized with other imaging techniques were found in 20 of the 37 patients. In 3 of 11 patients who were thought to have been surgically cured, and in 4 of 4 patients who were suspected of having carcinoids, octreotide scintigraphy showed abnormal accumulation of radioactivity. Histological or radiological evidence that additional sites noticed on octreotide scintigrams indeed represented tumour tissue was obtained in ten patients. Visualization of the carcinoids did not depend on the site of the tumour or on the presence or absence of hormonal hypersecretion, as measured by urinary 5-hydroxyindoleacetic acid and serum α-subunit concentrations. Apart from its use for tumour localization, octreotide scintigraphy, in consequence of its ability to demonstrate somatostatin receptor positive tumours, could be used to select those patients with the carcinoid syndrome who are likely to respond favourably to octreotide treatment.

DOI: 10.1007/BF00169802

Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title>Somatostatin analogue scintigraphy in carcinoid tumours</title>
<author>
<name>Dik J. Kwekkeboom</name>
<affiliation wicri:level="1">
<mods:affiliation>Department of Nuclear Medicine, University Hospital Dijkzigt, 40 Dr. Molewaterplein, 3015 GD, Rotterdam, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Nuclear Medicine, University Hospital Dijkzigt, 40 Dr. Molewaterplein, 3015 GD, Rotterdam</wicri:regionArea>
<wicri:noRegion>Rotterdam</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<mods:affiliation>Department of Internal Medicine, University Hospital Dijkzigt, 40 Dr. Molewaterplein, 3015 GD, Rotterdam, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Internal Medicine, University Hospital Dijkzigt, 40 Dr. Molewaterplein, 3015 GD, Rotterdam</wicri:regionArea>
<wicri:noRegion>Rotterdam</wicri:noRegion>
</affiliation>
</author>
<author>
<name>Eric P. Krenning</name>
<affiliation wicri:level="1">
<mods:affiliation>Department of Nuclear Medicine, University Hospital Dijkzigt, 40 Dr. Molewaterplein, 3015 GD, Rotterdam, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Nuclear Medicine, University Hospital Dijkzigt, 40 Dr. Molewaterplein, 3015 GD, Rotterdam</wicri:regionArea>
<wicri:noRegion>Rotterdam</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<mods:affiliation>Department of Internal Medicine, University Hospital Dijkzigt, 40 Dr. Molewaterplein, 3015 GD, Rotterdam, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Internal Medicine, University Hospital Dijkzigt, 40 Dr. Molewaterplein, 3015 GD, Rotterdam</wicri:regionArea>
<wicri:noRegion>Rotterdam</wicri:noRegion>
</affiliation>
</author>
<author>
<name>Willem H. Bakker</name>
<affiliation wicri:level="1">
<mods:affiliation>Department of Nuclear Medicine, University Hospital Dijkzigt, 40 Dr. Molewaterplein, 3015 GD, Rotterdam, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Nuclear Medicine, University Hospital Dijkzigt, 40 Dr. Molewaterplein, 3015 GD, Rotterdam</wicri:regionArea>
<wicri:noRegion>Rotterdam</wicri:noRegion>
</affiliation>
</author>
<author>
<name>H. Yoe Oei</name>
<affiliation wicri:level="1">
<mods:affiliation>Department of Nuclear Medicine, University Hospital Dijkzigt, 40 Dr. Molewaterplein, 3015 GD, Rotterdam, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Nuclear Medicine, University Hospital Dijkzigt, 40 Dr. Molewaterplein, 3015 GD, Rotterdam</wicri:regionArea>
<wicri:noRegion>Rotterdam</wicri:noRegion>
</affiliation>
</author>
<author>
<name>Peter P. M. Kooij</name>
<affiliation wicri:level="1">
<mods:affiliation>Department of Nuclear Medicine, University Hospital Dijkzigt, 40 Dr. Molewaterplein, 3015 GD, Rotterdam, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Nuclear Medicine, University Hospital Dijkzigt, 40 Dr. Molewaterplein, 3015 GD, Rotterdam</wicri:regionArea>
<wicri:noRegion>Rotterdam</wicri:noRegion>
</affiliation>
</author>
<author>
<name>Steven W.J. Lamberts</name>
<affiliation wicri:level="1">
<mods:affiliation>Department of Internal Medicine, University Hospital Dijkzigt, 40 Dr. Molewaterplein, 3015 GD, Rotterdam, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Internal Medicine, University Hospital Dijkzigt, 40 Dr. Molewaterplein, 3015 GD, Rotterdam</wicri:regionArea>
<wicri:noRegion>Rotterdam</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="RBID">ISTEX:259_1993_Article_BF00169802.pdf</idno>
<date when="1993">1993</date>
<idno type="doi">10.1007/BF00169802</idno>
<idno type="wicri:Area/Main/Corpus">000760</idno>
<idno type="wicri:Area/Main/Curation">000760</idno>
<idno type="wicri:Area/Main/Exploration">000239</idno>
</publicationStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Carcinoid</term>
<term>Octreotide scintigraphy</term>
<term>Somatostatin</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="eng">Scintigraphy with iodine-123 or indium-111 labelled somatostatin analogue (octreotide) was performed in 52 patients diagnosed as, suspected of, or at risk of having carcinoid tumours. In 32 of 37 (86%) patients in whom histologically proven carcinoids were still present, known tumour sites were visualized. Using 123I-coupled octreotide, 24 of 40 (60%) known extrahepatic sites were visualized, whereas all of 12 (100%) extrahepatic lesions were visualized after injection of 111In-coupled octreotide. Known liver metastases were not distinctly visualized with octreotide scintigraphy in 12 of 24 patients. In all but two of these cases, an even distribution of radioactivity in the liver was observed. This is most probably due to the fact that these liver metastases accumulated about as much radioactivity as does normal liver tissue. Previously unsuspected localizations or sites not recognized with other imaging techniques were found in 20 of the 37 patients. In 3 of 11 patients who were thought to have been surgically cured, and in 4 of 4 patients who were suspected of having carcinoids, octreotide scintigraphy showed abnormal accumulation of radioactivity. Histological or radiological evidence that additional sites noticed on octreotide scintigrams indeed represented tumour tissue was obtained in ten patients. Visualization of the carcinoids did not depend on the site of the tumour or on the presence or absence of hormonal hypersecretion, as measured by urinary 5-hydroxyindoleacetic acid and serum α-subunit concentrations. Apart from its use for tumour localization, octreotide scintigraphy, in consequence of its ability to demonstrate somatostatin receptor positive tumours, could be used to select those patients with the carcinoid syndrome who are likely to respond favourably to octreotide treatment.</div>
</front>
</TEI>
<mods xsi:schemaLocation="http://www.loc.gov/mods/v3 file:///applis/istex/home/loadistex/home/etc/xsd/mods.xsd" version="3.4" istexId="8261825d56f53cd12e9cb89f18a919b29209bbc9">
<titleInfo lang="eng">
<title>Somatostatin analogue scintigraphy in carcinoid tumours</title>
</titleInfo>
<name type="personal">
<namePart type="given">Dik J.</namePart>
<namePart type="family">Kwekkeboom</namePart>
<role>
<roleTerm type="text">author</roleTerm>
</role>
<affiliation>Department of Nuclear Medicine, University Hospital Dijkzigt, 40 Dr. Molewaterplein, 3015 GD, Rotterdam, The Netherlands</affiliation>
<affiliation>Department of Internal Medicine, University Hospital Dijkzigt, 40 Dr. Molewaterplein, 3015 GD, Rotterdam, The Netherlands</affiliation>
</name>
<name type="personal">
<namePart type="given">Eric P.</namePart>
<namePart type="family">Krenning</namePart>
<role>
<roleTerm type="text">author</roleTerm>
</role>
<affiliation>Department of Nuclear Medicine, University Hospital Dijkzigt, 40 Dr. Molewaterplein, 3015 GD, Rotterdam, The Netherlands</affiliation>
<affiliation>Department of Internal Medicine, University Hospital Dijkzigt, 40 Dr. Molewaterplein, 3015 GD, Rotterdam, The Netherlands</affiliation>
</name>
<name type="personal">
<namePart type="given">Willem H.</namePart>
<namePart type="family">Bakker</namePart>
<role>
<roleTerm type="text">author</roleTerm>
</role>
<affiliation>Department of Nuclear Medicine, University Hospital Dijkzigt, 40 Dr. Molewaterplein, 3015 GD, Rotterdam, The Netherlands</affiliation>
</name>
<name type="personal">
<namePart type="given">H. Yoe</namePart>
<namePart type="family">Oei</namePart>
<role>
<roleTerm type="text">author</roleTerm>
</role>
<affiliation>Department of Nuclear Medicine, University Hospital Dijkzigt, 40 Dr. Molewaterplein, 3015 GD, Rotterdam, The Netherlands</affiliation>
</name>
<name type="personal">
<namePart type="given">Peter P. M.</namePart>
<namePart type="family">Kooij</namePart>
<role>
<roleTerm type="text">author</roleTerm>
</role>
<affiliation>Department of Nuclear Medicine, University Hospital Dijkzigt, 40 Dr. Molewaterplein, 3015 GD, Rotterdam, The Netherlands</affiliation>
</name>
<name type="personal">
<namePart type="given">Steven W.J.</namePart>
<namePart type="family">Lamberts</namePart>
<role>
<roleTerm type="text">author</roleTerm>
</role>
<affiliation>Department of Internal Medicine, University Hospital Dijkzigt, 40 Dr. Molewaterplein, 3015 GD, Rotterdam, The Netherlands</affiliation>
</name>
<typeOfResource>text</typeOfResource>
<genre>Original Article</genre>
<genre>Original Paper</genre>
<originInfo>
<publisher>Springer-Verlag, Berlin/Heidelberg</publisher>
<dateCreated encoding="w3cdtf">1992-09-03</dateCreated>
<dateValid encoding="w3cdtf">2004-07-01</dateValid>
<copyrightDate encoding="w3cdtf">1993</copyrightDate>
</originInfo>
<language>
<languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<physicalDescription>
<internetMediaType>text/html</internetMediaType>
</physicalDescription>
<abstract lang="eng">Scintigraphy with iodine-123 or indium-111 labelled somatostatin analogue (octreotide) was performed in 52 patients diagnosed as, suspected of, or at risk of having carcinoid tumours. In 32 of 37 (86%) patients in whom histologically proven carcinoids were still present, known tumour sites were visualized. Using 123I-coupled octreotide, 24 of 40 (60%) known extrahepatic sites were visualized, whereas all of 12 (100%) extrahepatic lesions were visualized after injection of 111In-coupled octreotide. Known liver metastases were not distinctly visualized with octreotide scintigraphy in 12 of 24 patients. In all but two of these cases, an even distribution of radioactivity in the liver was observed. This is most probably due to the fact that these liver metastases accumulated about as much radioactivity as does normal liver tissue. Previously unsuspected localizations or sites not recognized with other imaging techniques were found in 20 of the 37 patients. In 3 of 11 patients who were thought to have been surgically cured, and in 4 of 4 patients who were suspected of having carcinoids, octreotide scintigraphy showed abnormal accumulation of radioactivity. Histological or radiological evidence that additional sites noticed on octreotide scintigrams indeed represented tumour tissue was obtained in ten patients. Visualization of the carcinoids did not depend on the site of the tumour or on the presence or absence of hormonal hypersecretion, as measured by urinary 5-hydroxyindoleacetic acid and serum α-subunit concentrations. Apart from its use for tumour localization, octreotide scintigraphy, in consequence of its ability to demonstrate somatostatin receptor positive tumours, could be used to select those patients with the carcinoid syndrome who are likely to respond favourably to octreotide treatment.</abstract>
<subject lang="eng">
<genre>Key words</genre>
<topic>Carcinoid</topic>
<topic>Octreotide scintigraphy</topic>
<topic>Somatostatin</topic>
</subject>
<relatedItem type="series">
<titleInfo type="abbreviated">
<title>Eur J Nucl Med</title>
</titleInfo>
<titleInfo>
<title>European Journal of Nuclear Medicine</title>
<partNumber>Year: 1993</partNumber>
<partNumber>Volume: 20</partNumber>
<partNumber>Number: 4</partNumber>
</titleInfo>
<genre>Archive Journal</genre>
<originInfo>
<dateIssued encoding="w3cdtf">1993-04-01</dateIssued>
<copyrightDate encoding="w3cdtf">1993</copyrightDate>
</originInfo>
<subject usage="primary">
<topic>Medicine & Public Health</topic>
<topic>Imaging / Radiology</topic>
<topic>Nuclear Medicine</topic>
</subject>
<identifier type="issn">0340-6997</identifier>
<identifier type="issn">Electronic: 1619-7089</identifier>
<identifier type="matrixNumber">259</identifier>
<identifier type="local">IssueArticleCount: 21</identifier>
<recordInfo>
<recordOrigin>Springer-Verlag, 1993</recordOrigin>
</recordInfo>
</relatedItem>
<identifier type="doi">10.1007/BF00169802</identifier>
<identifier type="matrixNumber">Art2</identifier>
<identifier type="local">BF00169802</identifier>
<accessCondition type="use and reproduction">MetadataGrant: OpenAccess</accessCondition>
<accessCondition type="use and reproduction">AbstractGrant: OpenAccess</accessCondition>
<accessCondition type="restriction on access">BodyPDFGrant: Restricted</accessCondition>
<accessCondition type="restriction on access">BodyHTMLGrant: Restricted</accessCondition>
<accessCondition type="restriction on access">BibliographyGrant: Restricted</accessCondition>
<accessCondition type="restriction on access">ESMGrant: Restricted</accessCondition>
<part>
<extent unit="pages">
<start>283</start>
<end>292</end>
</extent>
</part>
<recordInfo>
<recordOrigin>Springer-Verlag, 1993</recordOrigin>
<recordIdentifier>259_1993_Article_BF00169802.pdf</recordIdentifier>
</recordInfo>
</mods>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=IndiumV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000239 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000239 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=   *** parameter Area/wikiCode missing *** 
   |area=    IndiumV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:259_1993_Article_BF00169802.pdf
   |texte=   Somatostatin analogue scintigraphy in carcinoid tumours
}}

Wicri

This area was generated with Dilib version V0.5.81.
Data generation: Mon Aug 25 10:35:12 2014. Site generation: Thu Mar 7 10:08:40 2024